ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is BioCryst Pharmaceuticals, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 21.26% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -2.45
2
With a growth in Net Sales of 209.09%, the company declared Outstanding results in Sep 25
- The company has declared positive results for the last 11 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 49.99 MM
- RAW MATERIAL COST(Y) Fallen by -1.5% (YoY)
- DEBT-EQUITY RATIO (HY) Lowest at -121.08 %
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 20.00%, its profits have risen by 97.8%
4
Rising Promoter Confidence
- Promoters have increased their stake in the company by 5.39% over the previous quarter and currently hold 7.65% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to BioCryst Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is BioCryst Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
BioCryst Pharmaceuticals, Inc.
16.77%
0.93
51.55%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
62.14%
EBIT Growth (5y)
21.26%
EBIT to Interest (avg)
-2.45
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.16
Sales to Capital Employed (avg)
1.20
Tax Ratio
4.47%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
9.23%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-6.01
EV to EBIT
36.69
EV to EBITDA
36.07
EV to Capital Employed
38.99
EV to Sales
4.65
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
106.28%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend33What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 49.99 MM
RAW MATERIAL COST(Y)
Fallen by -1.5% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -121.08 %
INVENTORY TURNOVER RATIO(HY)
Highest at 2.66 times
DEBTORS TURNOVER RATIO(HY)
Highest at 7.32 times
NET SALES(Q)
At USD 159.4 MM has Grown at 36.14%
OPERATING PROFIT MARGIN(Q)
Highest at 18.77 %
PRE-TAX PROFIT(Q)
Highest at USD 14.87 MM
NET PROFIT(Q)
Highest at USD 15.64 MM
EPS(Q)
Highest at USD 0.06
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for BioCryst Pharmaceuticals, Inc.
Pre-Tax Profit
At USD 14.87 MM has Grown at 210.58%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 15.64 MM has Grown at 211.44%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD 49.99 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
At USD 159.4 MM has Grown at 36.14%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit Margin
Highest at 18.77 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 14.87 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 15.64 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 0.06
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Lowest at -121.08 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Inventory Turnover Ratio
Highest at 2.66 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 7.32 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -1.5% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
